Aileron Therapeutics, Inc. (ALRN)
Stock Price:
$2.11 USD
0.08 (3.94%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $2.00 -0.11 (-5.21%) Oct 22, 6:08 PM
Key Info
| Market Cap |
84.14M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-26.12M |
| Shares Out |
39.87M |
| EPS (ttm) |
-0.91 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$2.11 |
| Previous Close |
$2.03 |
| Change ($) |
0.08 |
| Change (%) |
3.94% |
| Day's Open |
2.12 |
| Day's Range |
2.02 - 2.21 |
| Day's Volume |
911,599 |
| 52-Week Range |
0.25 - 2.47 |
More Stats
| Market Cap |
84.14M |
| Enterprise Value |
70.05M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.87M |
| Float |
23.39M |
| EPS (basic) |
-0.91 |
| EPS (diluted) |
-0.91 |
| FCF / Share |
-0.77 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
756,539 |
| Short Ratio |
2.22 |
| Short % of Float |
3.23% |
| Beta |
3.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.64 |
| Revenue |
n/a |
| Operating Income |
-26.47M |
| Net Income |
-26.12M |
| Free Cash Flow |
-23.98M |
| Net Cash |
14.08M |
| Net Cash / Share |
0.35 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-50.02% |
| ROE |
-112.02% |
| ROIC |
-164.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.89*
(131.75% upside)
Low
2.00
Current: $2.11
High
8.00
Target: 4.89
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -29.96 | -31.90 | -23.01 | -18.17 | -12.89 |
| Net Income | -29.37 | -31.55 | -22.60 | -18.12 | -12.88 |
| Shares Outstanding | 24.54 | 14.74 | 7.44 | 0.43 | 0.40 |
| Earnings Per Share | -1.20 | -2.14 | -3.04 | -42.35 | -32.31 |
| Operating Cash Flow | -26.47 | -27.93 | -20.53 | -15.01 | -11.71 |
| Capital Expenditures | -0.15 | -4.42 | -0.14 | - | -0.09 |
| Free Cash Flow | -26.63 | -32.35 | -20.67 | -15.01 | -11.80 |
| Cash & Equivalents | 18.30 | 20.72 | 50.84 | 20.80 | 3.83 |
| Total Debt | 5.03 | 5.34 | - | - | - |
| Net Cash / Debt | 13.27 | 15.38 | 50.84 | 20.80 | 3.83 |
| Assets | 26.47 | 30.31 | 52.69 | 22.02 | 5.94 |
| Liabilities | 10.43 | 10.71 | 4.89 | 4.08 | 2.58 |
| Book Value | 16.05 | 19.60 | 47.80 | -112 | -94.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aileron Therapeutics, Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Manuel C. Aivado |
Stock Information
| Ticker Symbol |
ALRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALRN |
| IPO Date |
June 29, 2017 |
Description
Aileron Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.